Carboplatin Induction Chemotherapy in Clinically Lymph Node–positive Bladder Cancer

BACKGROUND: There are currently no guideline recommendations regarding the treatment of cisplatin-ineligible, clinically lymph node–positive (cN+) bladder cancer (BCa). OBJECTIVE: To investigate the oncological efficacy of gemcitabine/carboplatin induction chemotherapy (IC) in comparison to cisplati...

Descripción completa

Detalles Bibliográficos
Autores principales: von Deimling, Markus, Mertens, Laura S., van Rhijn, Bas W.G., Lotan, Yair, Spiess, Philippe E., Daneshmand, Siamak, Black, Peter C., Pallauf, Maximilian, D'Andrea, David, Moschini, Marco, Soria, Francesco, Del Giudice, Francesco, Afferi, Luca, Laukhtina, Ekaterina, Yanagisawa, Takafumi, Kawada, Tatsushi, Teoh, Jeremy Y.-C., Abufaraj, Mohammad, Ploussard, Guillaume, Roumiguié, Mathieu, Karakiewicz, Pierre I., Babjuk, Marko, Gontero, Paolo, Xylinas, Evanguelos, Rink, Michael, Shariat, Shahrokh F., Pradere, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Bladder Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175724/
https://www.ncbi.nlm.nih.gov/pubmed/37187719
http://dx.doi.org/10.1016/j.euros.2023.02.014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175724/
https://www.ncbi.nlm.nih.gov/pubmed/37187719
http://dx.doi.org/10.1016/j.euros.2023.02.014

Ejemplares similares